In this study, 89Zr‐Df‐Tinurilimab showed a high tumor uptake at around 17% ID g−1 and low uptake in other nontarget organs in CEACAM6‐positive models, providing excellent tumor contrast. Here, CEACAM6 is linked to neoplasm.